Hypothesis/aims of study. Preeclampsia is a serious pregnancy-specific multi-organ disease of complex etiology. It affects 36% of expectant mothers worldwide and it persists as a leading cause of maternal and fetal morbidity and mortality. This study aimed at analyzing the frequency of preeclampsia in women with different somatotypes and at developing a prediction model to determine the risk of this disease. Study design, materials and methods. 390 women were examined, of whom 110 were of the macrosomatic type, 173 of the mesosomatic type, and 107 of the microsomatic type. Somatometry was performed according to R.N. Dorokhov in women in early pregnancy (before 910 weeks of gestation). The urinary excretion of markers for podocyte injury (nephrin, podocalyxin, and VEGF) was measured using ELISA spectrophotometric methods. Results. Preeclampsia has been found to be significantly more prevalent among the representatives of the macrosomatic type, compared to women of the meso- and microsomatic types. Urine nephrin, podocalyxin and VEGF levels were significantly higher in women of the macrosomatic type, as compared to those of the meso- and microsomatic types. Using multiple regression analysis, we obtained the regression equation (formula), which predicts the development of preeclampsia in women of different somatotypes. Conclusion. Carrying out calculations according to the presented formula allows predicting the occurrence of preeclampsia with high accuracy, as well as forming high-risk groups among patients already in the first trimester of pregnancy when a pregnant woman is registered in the womens consultation, long before the disease develops. This will contribute to more effective implementation of therapeutic measures to prevent the development of this complication.
Hypothesis/aims of study. Poor placental vascularization can lead to placental insufficiency, due to which the metabolism of nutrients and microelements between the maternal and fetal blood circulations subsequently decreases. Due to poor perfusion of placental vessels, placental dysfunction occurs. Chronic fetal hypoxia causes fetal growth retardation. The aim of this study was to assess the frequency of placental insufficiency in women with different somatotypes and to develop a model for predicting the risk of this pathology. Study design, materials and methods. A total of 390 women were examined, of whom 110 were macrosomatic, 173 mesosomatic, and 107 microsomatic. Somatometry was performed according to R.N. Dorokhov for women in the early stages of pregnancy (up to 9-10 weeks). Placental insufficiency markers (VEGF, PlGF, IL-6, and endocan-1) were determined spectrophotometrically in blood serum at the gestational age of 1213 and 2223 weeks using ELISA methods. Results. Placental insufficiency was significantly more prevalent among the women of the macro- and microsomatic body type compared with those of mesosomatotypes (p 0.05). In pregnant women with subsequent placental insufficiency, VEGF and PlGF serum levels at 1213 weeks were lower, when compared to those in patients who did not develop pathology (p 0.05), and the levels of serum endocan-1 and IL-6 were higher in comparison with those in individuals who did not develop pathology (p 0.05). Using multiple regression analysis, we obtained the regression equation (formula), which predicts the development of placental insufficiency in women of different somatotypes. Conclusion. The resulting formula allows us to accurately predict the development of placental insufficiency and to form high-risk groups among women for the development of this disease. This will contribute to the effective implementation of therapeutic and preventive measures to avert the development of this pathology.
BACKGROUND: Anemia during pregnancy, undiagnosed and untreated promptly, is the cause of various obstetric complications: spontaneous miscarriages, premature birth, placental insufficiency, obstetric bleeding, ante- and intrapartum fetal death. AIM: The aim of this study was to evaluate the incidence of iron deficiency anemia in pregnant women with different somatotypes and to develop a prognostic model for the pathology onset. MATERIALS AND METHODS: We examined 390 pregnant women. Somatometry was performed according to the method of R.N. Dorokhov in terms of pregnancy not exceeding 9-10 weeks. Of the examined pregnant women, 110 were of the macrosomatotype, 173 of the meso- and 107 of the microsomatotype. In a clinical blood test, the levels of hemoglobin and red blood cells were determined using well-known methods. Blood iron levels were evaluated by the colorimetric method with ferrozine using a Parma Iron Reagents Kit (Parma Diagnostics Ltd., Russia). Serum hepcidin levels were determined spectrophotometrically using ELISA methods. RESULTS: Iron deficiency anemia was most commonly detected in pregnant women of the macro- and microsomatotype, when compared to those of the mesosomatotype (p 0.05). There was no severe anemia in the study groups. The levels of hematological parameters (serum iron and serum hepcidin) were significantly higher in the group of pregnant women with latent anemia, compared to the study group without signs of anemia (p 0.05). In the second trimester, iron deficiency anemia occurred in the group of patients with latent anemia. Using multiple regression analysis, a formula was obtained for predicting the onset of iron deficiency anemia in pregnant women of different somatotypes. CONCLUSIONS: Hematological parameters (serum iron and serum hepcidin) should be attributed to markers of iron deficiency anemia and timely predict the onset of pathology. The mathematical formula obtained allows predicting with high accuracy the onset of iron deficiency anemia in pregnant women, taking into account the somatotype in the first trimester of pregnancy, and timely preventing the onset of pathology.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.